Application of plpp4 as a target for diagnosis, treatment and prognosis of non-small cell lung cancer

Abstract

The invention discloses the application of PLPP4 as a target for diagnosis, treatment and prognosis of non-small cell lung cancer. The present invention finds that PLPP4 (phosphatidic acid phospholipase 4) is highly expressed in tumor tissues and cell lines of non-small cell lung cancer, and that high expression of PLPP4 in lung malignant tumor tissues is associated with poor clinicopathological grading, and is associated with short overall survival time and Progression-free survival time is related, and silencing PLPP4 can affect the proliferation of non-small cell lung cancer cells in vitro and tumorigenesis in vivo. This information indicates that PLPP4 can be used as a target for the diagnosis, treatment and prognosis of non-small cell lung cancer. The invention utilizes the primers for fluorescent quantitative detection of PLPP4 as a reagent for the diagnosis and prognosis of non-small cell lung cancer; the LNA-modified sisiRNA that specifically silences PLPP4 is used as a therapeutic agent for non-small cell lung cancer.

Description

technical field [0001] The invention belongs to a new application of PLPP4, and specifically relates to the application of PLPP4 as a target for diagnosis, treatment and prognosis of non-small cell lung cancer. Background technique [0002] Lung cancer (Lung cancer) is the tumor with the highest incidence and mortality in the world. In 2012, there were about 1.8 million new cases of lung cancer in the world, accounting for 13% of all tumor cases; the male incidence rate was 52.4 cases per 100,000 people, and the death rate The rate was 32.0 cases / 100,000, the female incidence rate was 15.4 cases / 100,000, and the fatality rate was 12.1 cases / 100,000. Lung cancer is also the malignant tumor with the highest incidence and mortality rate in China. In 2015, the total incidence rate in my country was 34.4 cases / 100,000 people, and the fatality rate was 27.5 cases / 100,000 people, both of which were higher than the world average; and many studies have shown that my country The incid...

AI Technical Summary

Problems solved by technology

[0004] So far, NSCLC prognosis assessment based on abnormal gene expression is still immature. On the one hand, genotyping methods based on gene expression differences cannot fully reflect the clinical prognostic characteristics of patients with non-small cell lung cancer; on the other hand, Among the factors affecting the survival and prognosis of patients with non-small cell lung cancer, in addition to the progress of the malignant tumor itself, it is also mixed with various influences of the patient's body itself

Images